Assay ID | Title | Year | Journal | Article |
AID117314 | Percent increase in median life span of BDF1 mice with advanced P-388 leukemia at dose 12.5 mg/kg administered intraperitoneally; 4, 8, 12 days of ip treatment relative to tumor inoculation | 1982 | Journal of medicinal chemistry, May, Volume: 25, Issue:5
| Antitumor agents. 2. Bisguanylhydrazones of anthracene-9,10-dicarboxaldehydes. |
AID112614 | Antitumor activity against B-16 melanoma in BDF1 mice expressed as percentage increase in life span at optimum dose of 6 mg/kg | 1993 | Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
| N-phosphoryl derivatives of bisantrene. Antitumor prodrugs with enhanced solubility and reduced potential for toxicity. |
AID117148 | Percent increase in median life span of BDF1 mice with Colon 26 at dose 6.2 mg/kg administered intraperitoneally; Range is 114-150%; 1, 5, 9 days of ip treatment relative to tumor inoculation | 1982 | Journal of medicinal chemistry, May, Volume: 25, Issue:5
| Antitumor agents. 2. Bisguanylhydrazones of anthracene-9,10-dicarboxaldehydes. |
AID8254 | Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill) | 1987 | Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
| New antitumor agents containing the anthracene nucleus. |
AID211311 | Percent of DNA remaining uncut after incubation with Topoisomerase II at 1 uM concentration | 1998 | Bioorganic & medicinal chemistry letters, Jan-20, Volume: 8, Issue:2
| Synthesis, DNA-damaging and cytotoxic properties of novel topoisomerase II-directed bisantrene analogues. |
AID681572 | TP_TRANSPORTER: drug resistance in BCRP-expressing MEF3.8 cells | 2003 | Cancer research, Mar-15, Volume: 63, Issue:6
| Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein. |
AID110621 | Cures is the number of survivors of the total treated mice (10) with P-388 leukemia, at 30 days. | 1982 | Journal of medicinal chemistry, May, Volume: 25, Issue:5
| Antitumor agents. 2. Bisguanylhydrazones of anthracene-9,10-dicarboxaldehydes. |
AID201221 | Bacterial mutagenicity was measured against Salmonella Typhimurium TA1538 at dose range of 0-200 ug/plate | 1998 | Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
| Anthracene-9,10-diones as potential anticancer agents: bacterial mutation studies of amido-substituted derivatives reveal an unexpected lack of mutagenicity. |
AID54963 | Cubic spline relative binding strength was determined by using spectrophotometric titration | 1990 | Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
| DNA binding by antitumor anthracene derivatives. |
AID8415 | Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL | 1987 | Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
| New antitumor agents containing the anthracene nucleus. |
AID540068 | Inhibition of human recombinant NQO1 at 100 uM | 2010 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
| In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). |
AID1079933 | Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is | | | |
AID55006 | delta Tm value is the difference between Tm(melting temperature) for calf thymus DNA with drug and without drug(Tm = 71 degree C for DNA alone) | 1990 | Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
| DNA binding by antitumor anthracene derivatives. |
AID110622 | Cures is the number of survivors of the total treated mice (10) with advanced B-16 melanoma, at 30 days. | 1982 | Journal of medicinal chemistry, May, Volume: 25, Issue:5
| Antitumor agents. 2. Bisguanylhydrazones of anthracene-9,10-dicarboxaldehydes. |
AID95083 | Effect on RNA synthesis was determined by incorporation of radioligand into L1210 murine leukemia at a concentration of 10 ug/mL (*: >1 log cell kill) | 1987 | Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
| New antitumor agents containing the anthracene nucleus. |
AID88859 | Antitumor potency against human ovarian cancer cells in clonogenic assay | 1990 | Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
| DNA binding by antitumor anthracene derivatives. |
AID110630 | Cures is the number of survivors of the total treated mice (42) with P-388 leukemia, at 30 days. | 1982 | Journal of medicinal chemistry, May, Volume: 25, Issue:5
| Antitumor agents. 2. Bisguanylhydrazones of anthracene-9,10-dicarboxaldehydes. |
AID95078 | Effect on DNA synthesis was determined by incorporation of radioligand into L1210 murine leukemia at a concentration of 1 ug/mL. (*: >50% cell kill) | 1987 | Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
| New antitumor agents containing the anthracene nucleus. |
AID1079944 | Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source] | | | |
AID110626 | Cures is the number of survivors of the total treated mice (20) with B-16 melanoma, at 60 days. | 1982 | Journal of medicinal chemistry, May, Volume: 25, Issue:5
| Antitumor agents. 2. Bisguanylhydrazones of anthracene-9,10-dicarboxaldehydes. |
AID117138 | Percent increase in median life span of BDF1 mice with B-16 melanoma at dose 6 mg/kg administered intraperitoneally; range 98-122%; 1-9 days of ip treatment relative to tumor inoculation | 1982 | Journal of medicinal chemistry, May, Volume: 25, Issue:5
| Antitumor agents. 2. Bisguanylhydrazones of anthracene-9,10-dicarboxaldehydes. |
AID112757 | Antitumor activity against P388 leukemia in BDF1/CDF1 mice expressed as percentage increase in life span at optimum dose of 12.5 mg/kg | 1993 | Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
| N-phosphoryl derivatives of bisantrene. Antitumor prodrugs with enhanced solubility and reduced potential for toxicity. |
AID1079947 | Comments (NB not yet translated). [column 'COMMENTAIRES' in source] | | | |
AID277029 | Inhibition of human recombinant NQO1 | 2006 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 16, Issue:24
| In silico identification and biochemical characterization of novel inhibitors of NQO1. |
AID8248 | Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL | 1987 | Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
| New antitumor agents containing the anthracene nucleus. |
AID8412 | Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill) | 1987 | Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
| New antitumor agents containing the anthracene nucleus. |
AID26641 | pKa value for amino group in the compound | 1990 | Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
| DNA binding by antitumor anthracene derivatives. |
AID117316 | Percent increase in median life span of BDF1 mice with madison lung 109 leukemia administered intraperitoneally | 1982 | Journal of medicinal chemistry, May, Volume: 25, Issue:5
| Antitumor agents. 2. Bisguanylhydrazones of anthracene-9,10-dicarboxaldehydes. |
AID110634 | Cures is the number of survivors of the total treated mice (6) with P-388 leukemia, at 30 days. | 1982 | Journal of medicinal chemistry, May, Volume: 25, Issue:5
| Antitumor agents. 2. Bisguanylhydrazones of anthracene-9,10-dicarboxaldehydes. |
AID95081 | Effect on RNA synthesis was determined by incorporation of radioligand into L1210 murine leukemia at a concentration of 0.01 ug/mL | 1987 | Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
| New antitumor agents containing the anthracene nucleus. |
AID95075 | Effect on DNA synthesis was determined by incorporation of radioligand into L1210 murine leukemia at a concentration of 0.1 ug/mL | 1987 | Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
| New antitumor agents containing the anthracene nucleus. |
AID143570 | Compound was tested for potency against human myeloma 8226 cells (40 fold resistant to doxorubicin). | 1997 | Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
| 1,4-disubstituted anthracene antitumor agents. |
AID1079948 | Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source] | | | |
AID8423 | In vitro inhibition of human 8226 myeloma tumor cell line growth. | 1987 | Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
| New antitumor agents containing the anthracene nucleus. |
AID201225 | Bacterial mutagenicity was measured against Salmonella Typhimurium TA98 at dose range of 0-20 ug/plate | 1998 | Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
| Anthracene-9,10-diones as potential anticancer agents: bacterial mutation studies of amido-substituted derivatives reveal an unexpected lack of mutagenicity. |
AID211310 | Percent of DNA remaining uncut after incubation with Topoisomerase II at 0.1 uM concentration | 1998 | Bioorganic & medicinal chemistry letters, Jan-20, Volume: 8, Issue:2
| Synthesis, DNA-damaging and cytotoxic properties of novel topoisomerase II-directed bisantrene analogues. |
AID95225 | Effect on protein synthesis was determined by incorporation of radioligand into L1210 murine leukemia at a concentration of 1 ug/mL. (*: >50% cell kill) | 1987 | Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
| New antitumor agents containing the anthracene nucleus. |
AID1079931 | Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source] | | | |
AID1079935 | Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source] | | | |
AID8407 | Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL | 1987 | Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
| New antitumor agents containing the anthracene nucleus. |
AID110624 | Cures is the number of survivors of the total treated mice (17) with L-1210 leukemia, at 30 days. | 1982 | Journal of medicinal chemistry, May, Volume: 25, Issue:5
| Antitumor agents. 2. Bisguanylhydrazones of anthracene-9,10-dicarboxaldehydes. |
AID214777 | In vitro inhibition of human UACC-66 ovarian tumor cell line growth. | 1987 | Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
| New antitumor agents containing the anthracene nucleus. |
AID201679 | Compound was tested for potency against human colon carcinoma SW 480 cells in a sulforhodamine B assay. | 1997 | Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
| 1,4-disubstituted anthracene antitumor agents. |
AID117305 | Percent increase in median life span of BDF1 mice with advanced B-16 melanoma at dose 12.5 mg/kg administered intraperitoneally; 5, 9, 13 days of ip treatment relative to tumor inoculation | 1982 | Journal of medicinal chemistry, May, Volume: 25, Issue:5
| Antitumor agents. 2. Bisguanylhydrazones of anthracene-9,10-dicarboxaldehydes. |
AID8408 | Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL | 1987 | Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
| New antitumor agents containing the anthracene nucleus. |
AID117157 | Percent increase in median life span of BDF1 mice with P-388 leukemia at dose 12.5 mg/kg administered intraperitoneally; 1, 5, 9 days of ip treatment relative to tumor inoculation | 1982 | Journal of medicinal chemistry, May, Volume: 25, Issue:5
| Antitumor agents. 2. Bisguanylhydrazones of anthracene-9,10-dicarboxaldehydes. |
AID82014 | Tested in vitro for inhibitory activity of human tumor cell growth against HEC 1A endometrial tumor, by using clonogenic assays. | 1987 | Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
| New antitumor agents containing the anthracene nucleus. |
AID110627 | Cures is the number of survivors of the total treated mice (20) with Colon 26, at 60 days. | 1982 | Journal of medicinal chemistry, May, Volume: 25, Issue:5
| Antitumor agents. 2. Bisguanylhydrazones of anthracene-9,10-dicarboxaldehydes. |
AID143571 | Compound was tested for potency against human myeloma 8226 cells using MTT assay method. | 1997 | Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
| 1,4-disubstituted anthracene antitumor agents. |
AID8249 | Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL | 1987 | Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
| New antitumor agents containing the anthracene nucleus. |
AID8416 | Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL | 1987 | Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
| New antitumor agents containing the anthracene nucleus. |
AID8413 | Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill) | 1987 | Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
| New antitumor agents containing the anthracene nucleus. |
AID110639 | Cures is the number of survivors of the total treated mice (6) with advanced L-1210 leukemia; treatment day +2 iv | 1982 | Journal of medicinal chemistry, May, Volume: 25, Issue:5
| Antitumor agents. 2. Bisguanylhydrazones of anthracene-9,10-dicarboxaldehydes. |
AID26757 | DNA binding dissociation constant as KD; No data | 1984 | Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
| Interactions of antitumor drugs with natural DNA: 1H NMR study of binding mode and kinetics. |
AID1079936 | Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source] | | | |
AID95082 | Effect on RNA synthesis was determined by incorporation of radioligand into L1210 murine leukemia at a concentration of 0.1 ug/mL | 1987 | Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
| New antitumor agents containing the anthracene nucleus. |
AID1079946 | Presence of at least one case with successful reintroduction. [column 'REINT' in source] | | | |
AID95224 | Effect on protein synthesis was determined by incorporation of radioligand into L1210 murine leukemia at a concentration of 10 ug/mL (*: >1 log cell kill) | 1987 | Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
| New antitumor agents containing the anthracene nucleus. |
AID122575 | Number of survivors after treating 12 mice (infected with B16 melanoma) for 60 days | 1993 | Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
| N-phosphoryl derivatives of bisantrene. Antitumor prodrugs with enhanced solubility and reduced potential for toxicity. |
AID216581 | Compound was tested for potency against human colon carcinoma WiDr cells in a sulforhodamine B assay. | 1997 | Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
| 1,4-disubstituted anthracene antitumor agents. |
AID54620 | Apparent binding constant (McGhee-von Hippel) was determined by using spectrophotometric titration | 1990 | Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
| DNA binding by antitumor anthracene derivatives. |
AID110799 | Number of survivors after treating 42 mice (infected with P388 leukemia) for 30 days | 1993 | Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
| N-phosphoryl derivatives of bisantrene. Antitumor prodrugs with enhanced solubility and reduced potential for toxicity. |
AID1079949 | Proposed mechanism(s) of liver damage. [column 'MEC' in source] | | | |
AID8493 | Compound was tested for potency against human lung A549 cells using sulforhodamine B assay. | 1997 | Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
| 1,4-disubstituted anthracene antitumor agents. |
AID8421 | Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill) | 1987 | Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
| New antitumor agents containing the anthracene nucleus. |
AID95074 | Effect on DNA synthesis was determined by incorporation of radioligand into L1210 murine leukemia at a concentration of 0.01 ug/mL | 1987 | Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
| New antitumor agents containing the anthracene nucleus. |
AID1079945 | Animal toxicity known. [column 'TOXIC' in source] | | | |
AID117308 | Percent increase in median life span of BDF1 mice with advanced L-1210 leukemia | 1982 | Journal of medicinal chemistry, May, Volume: 25, Issue:5
| Antitumor agents. 2. Bisguanylhydrazones of anthracene-9,10-dicarboxaldehydes. |
AID95217 | Effect on RNA synthesis was determined by incorporation of radioligand into L1210 murine leukemia at a concentration of 1 ug/mL. (*: >50% cell kill) | 1987 | Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
| New antitumor agents containing the anthracene nucleus. |
AID123620 | Percent tumor inhibition at non-lethal dose was determined in BDF1 mice with madison lung 109 leukemia; 1, 5, 9 days of sc treatment relative to tumor inoculation | 1982 | Journal of medicinal chemistry, May, Volume: 25, Issue:5
| Antitumor agents. 2. Bisguanylhydrazones of anthracene-9,10-dicarboxaldehydes. |
AID1079942 | Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source] | | | |
AID98398 | Compound was tested for potency against multidrug-resistant murine leukemia L1210 cells | 1997 | Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
| 1,4-disubstituted anthracene antitumor agents. |
AID8420 | Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill) | 1987 | Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
| New antitumor agents containing the anthracene nucleus. |
AID9989 | Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line | 1998 | Bioorganic & medicinal chemistry letters, Jan-20, Volume: 8, Issue:2
| Synthesis, DNA-damaging and cytotoxic properties of novel topoisomerase II-directed bisantrene analogues. |
AID680880 | TP_TRANSPORTER: efflux in S1-B1-20 cells | 1994 | Oncology research, , Volume: 6, Issue:7
| P-glycoprotein mediates profound resistance to bisantrene. |
AID8255 | Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill) | 1987 | Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
| New antitumor agents containing the anthracene nucleus. |
AID98397 | Compound was tested for potency against multi drug resistant murine leukemia L1210 cells. | 1997 | Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
| 1,4-disubstituted anthracene antitumor agents. |
AID1079941 | Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source] | | | |
AID1079937 | Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source] | | | |
AID95222 | Effect on protein synthesis was determined by incorporation of radioligand into L1210 murine leukemia at a concentration of 0.1 ug/mL | 1987 | Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
| New antitumor agents containing the anthracene nucleus. |
AID211312 | Percent of DNA remaining uncut after incubation with Topoisomerase II at 10 uM concentration | 1998 | Bioorganic & medicinal chemistry letters, Jan-20, Volume: 8, Issue:2
| Synthesis, DNA-damaging and cytotoxic properties of novel topoisomerase II-directed bisantrene analogues. |
AID1079940 | Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source] | | | |
AID216123 | Tested in vitro for inhibitory activity of human tumor cell growth against WIDR colon tumor, by using clonogenic assays. | 1987 | Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
| New antitumor agents containing the anthracene nucleus. |
AID95221 | Effect on protein synthesis was determined by incorporation of radioligand into L1210 murine leukemia at a concentration of 0.01 ug/mL | 1987 | Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
| New antitumor agents containing the anthracene nucleus. |
AID1079939 | Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source] | | | |
AID540069 | Inhibition of human recombinant NQO2 at 100 uM | 2010 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
| In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). |
AID1079932 | Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source] | | | |
AID1079938 | Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source] | | | |
AID201223 | Bacterial mutagenicity was measured against Salmonella Typhimurium TA97a at dose range of 0-400 ug/plate | 1998 | Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
| Anthracene-9,10-diones as potential anticancer agents: bacterial mutation studies of amido-substituted derivatives reveal an unexpected lack of mutagenicity. |
AID95077 | Effect on DNA synthesis was determined by incorporation of radioligand into L1210 murine leukemia at a concentration of 10 ug/mL (*: >1 log cell kill) | 1987 | Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
| New antitumor agents containing the anthracene nucleus. |
AID1079934 | Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source] | | | |
AID82834 | Cell cytotoxicity was determined against human promyelocytic leukemia (HL60) cell line | 1998 | Bioorganic & medicinal chemistry letters, Jan-20, Volume: 8, Issue:2
| Synthesis, DNA-damaging and cytotoxic properties of novel topoisomerase II-directed bisantrene analogues. |
AID117149 | Percent increase in median life span of BDF1 mice with L-1210 leukemia at dose 12.5 mg/kg administered intraperitoneally; 1, 5, 9 days of ip treatment relative to tumor inoculation | 1982 | Journal of medicinal chemistry, May, Volume: 25, Issue:5
| Antitumor agents. 2. Bisguanylhydrazones of anthracene-9,10-dicarboxaldehydes. |
AID1079943 | Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source] | | | |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |